Pricing Zolgensma – the world’s most expensive drug

Pricing Zolgensma – the world’s most expensive drug

Saved in:

Bibliographic Details
Main Author:	Mark Nuijten
Format:	Article
Language:	English
Published:	MDPI AG 2022-12-01
Series:	Journal of Market Access & Health Policy
Subjects:	price valuation reimbursement orphan disease
Online Access:	http://dx.doi.org/10.1080/20016689.2021.2022353
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pricing of orphan drugs in oncology and rare diseases
by: Mark Nuijten, et al.
Published: (2020-01-01)

Are payers treating orphan drugs differently?
by: Joshua P. Cohen, et al.
Published: (2014-01-01)

Analysing criteria for price and reimbursement of orphan drugs in Spain
by: Xavier Badia, et al.
Published: (2019-07-01)

An integrated valuation model for payer and investor
by: Mark Nuijten, et al.
Published: (2022-12-01)

Valuation of Medical Innovation Handling with Uncertainty and Risk
by: Mark Nuijten, et al.
Published: (2024-08-01)

A comparative study of orphan drug prices in Europe
by: Katherine Eve Young, et al.
Published: (2017-01-01)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
by: Bérengère Macabeo, et al.
Published: (2023-12-01)

Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe
by: Goran Medic, et al.
Published: (2017-01-01)

Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview
by: Naina R. Verghese, et al.
Published: (2019-01-01)

Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
by: Hajer Dahmani, et al.
Published: (2023-12-01)

ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION
by: M. V. Sura, et al.
Published: (2015-03-01)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
by: Karolina Badora, et al.
Published: (2017-01-01)

The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change
by: K. E. Young, et al.
Published: (2017-01-01)

IS RUSSIA READY FOR THE INTRODUCTION OF THE NATIONAL REFERENCE PRICING SYSTEM?
by: V. V. Omelyanovskiy
Published: (2015-05-01)

Debates over orphan drug pricing: a meta-narrative literature review
by: Matthew S. Hanchard
Published: (2025-03-01)

Application of four pricing models for orphan medicines: a case study for lumasiran
by: Noa Rosenberg, et al.
Published: (2024-12-01)

On the distribution of prices in market real estate and «offset» estimations of market value
by: N. P. Barinov, et al.
Published: (2016-10-01)

Visual Research of Global Orphan Drug from a Bibliometric Perspective
by: Wen X, et al.
Published: (2025-05-01)

Non-profit drug research and development: the case study of Genethon
by: Szymon Jarosławski, et al.
Published: (2019-01-01)

Değer ve Değerleme Hakkında Kavramsal ve Kuramsal Bir Çalışma
by: Mustafa Gözen
Published: (2019-11-01)

Orphan diseases — rare but important!
by: article Editorial
Published: (2019-06-01)

ROAD MAP FOR DEVELOPMENT OF PRICE REGULATION SYSTEM AND SYSTEM OF DRUG SUPPLY AT THE EXPENSE OF RUSSIAN FEDERATION HEALTHCARE SYSTEM FUNDS
by: M. V. Sura, et al.
Published: (2015-05-01)

Features of intellectual property protection mechanisms on the example of orphan drugs circulation
by: D. S. Yurochkin, et al.
Published: (2022-01-01)

What is the role of antineoplastic drug safety in reimbursement decision making?
by: A. S. Kolbin, et al.
Published: (2018-11-01)

Current Problems in Provision of Orphan Drugs and Ways to Solve Them
by: Alexei S. Kolbin, et al.
Published: (2016-09-01)

Getting Ours? “Girlbossing” and the Ethics of Nurse Reimbursement Models
by: Danisha Jenkins, et al.
Published: (2024-12-01)

IMPACT OF THE WORLD PRICES ON THE NATIONAL PRICING SYSTEM
by: Yuri A. Sarukhanyan
Published: (2017-12-01)

Accelerating patient access to oncology medicines with multiple indications in Europe
by: R. Lawlor, et al.
Published: (2021-01-01)

The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease
by: Jesper Jørgensen, et al.
Published: (2018-01-01)

Should annual cost of the drug inform reimbursement decisions? A perspective from China’s healthcare security system
by: Xiaochen Peng, et al.
Published: (2025-04-01)

Protective behaviours among orphaned learners in a district of Gauteng province, South Africa
by: Thembi V. Simbeni, et al.
Published: (2025-03-01)

EMA approved orphan medicines since the implementation of the orphan legislation
by: Eveliina Hahl, et al.
Published: (2025-06-01)

Valuation of urban green open space using the Hedonic price model
by: R. Setiowati, et al.
Published: (2024-01-01)

REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS
by: Andrey Vladislavovich Pavlysh, et al.
Published: (2015-09-01)

PAYMENT OF NEW EXPENSIVE TECHNOLOGIES IN HEALTH CARE ON THE BASIS OF RISKS -SHARING AGREEMENTS: POSSIBILITIES OF APPLICATION IN THE RUSSIAN FEDERATION
by: L. S. Melnikova
Published: (2015-06-01)

Quantifying the persisting orphan-drug shortage public health crisis in the United States
by: Szymon Jarosławski, et al.
Published: (2017-01-01)

SOCIO-CULTURAL ADAPTATION OF CHILDREN-ORPHANS BY LITERATURE
by: N. Yushkina
Published: (2018-03-01)

Unlocking the potential of established products: toward new incentives rewarding innovation in Europe
by: Gabrielle Nayroles, et al.
Published: (2017-01-01)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
by: Zoltán Kaló, et al.
Published: (2017-01-01)

Original drugs approved by the Food and Drug Administration (Center for Drug Evaluation and Research) in 2024
by: D. V. Kurkin, et al.
Published: (2025-07-01)